MOBIDIAG
1.3.2021 07:02:07 CET | Business Wire | Press release
Mobidiag Ltd. today announces that it has received CE-IVD marking for its Amplidiag® RESP-4 molecular diagnostic test for the rapid and simultaneous detection of some of the most prevalent respiratory viruses: SARS-CoV-2 (responsible for COVID-19 infection), Influenza A, Influenza B and RSV.
These viruses present similar symptoms, making it difficult for physicians to determine accurately which virus a patient has. The Amplidiag® RESP-4 assay can rapidly and simultaneously determine an accurate diagnosis from one patient sample using nasopharyngeal swabs, helping to guide clinicians to the relevant treatment decision for each patient. The test runs on the Mobidiag Amplidiag® Easy platform , which provides clinicians with an optimized sample screening process, with automated DNA/RNA extraction and PCR plate setup. Based on well-established high-throughput PCR technology, the platform can process 46 samples in approximately three hours.
This new test further broadens Mobidiag’s already available portfolio of diagnostics tests.
Tuomas Tenkanen, CEO of Mobidiag said, “We are very pleased to announce the CE-IVD marking for the Amplidiag® RESP-4 assay, which is highly relevant to both the traditional flu season and COVID-19. Symptoms caused by these viruses [SARS-CoV-2, Influenza A, Influenza B and RSV] can be very similar, and it is imperative that healthcare professionals are able to rapidly distinguish between them, in order to start the appropriate treatment for the benefit of patients.
In response to the growing need for fast and reliable diagnostics, at Mobidiag we are putting all our efforts into maintaining a high degree of autonomy in the production of our Amplidiag® tests by securing critical components to provide continuous support for our customers, as we all work together to control the spread of COVID-19.”
Mobidiag is currently developing Novodiag® RESP-4, a molecular diagnostic test using its Novodiag® platform for the rapid and on-demand detection of SARS-CoV-2, Influenza A, Influenza B and RSV. This test will complement Amplidiag® RESP-4 and enable clinicians to detect respiratory viruses to support early decisions in managing efficiently epidemiological and infection control measures, isolate patients in a timely manner, and ultimately improve patient care and outcomes.
Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Please follow the recommended processes and guidance for your location if you have any symptoms of respiratory infections.
Notes to editors
About Mobidiag Ltd
Mobidiag is a fast-growing molecular diagnostics company whose rapid, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210228005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Laprophan Completes the Acquisition of Rivopharm, Accelerating Its International Expansion Strategy17.6.2026 14:39:00 CEST | Press release
Laprophan Group, the pioneer and one of Morocco's leading pharmaceutical groups, today announced the successful completion of the acquisition of a controlling stake in Rivopharm, a Switzerland-based pharmaceutical company specialized in specialty medicines, dossier development, complex formulations and value-added pharmaceutical solutions, and operating its own industrial manufacturing site. The financial terms of the transaction were not disclosed. Rivopharm generates annual revenue of approximately US$100 million. The acquisition represents a transformational milestone in Laprophan's development and marks the Group's first acquisition in Europe. The transaction significantly strengthens Laprophan's European footprint and accelerates its ambition to build a differentiated international pharmaceutical platform spanning Europe, Africa, the Middle East and selected global markets. The acquisition was carried out through Europhan, Laprophan's Luxembourg-based European platform, reinforcin
Rehlko and Liebherr Partner on Strategic Capacity Expansion to Support Accelerating Data Center Demand for Resilient Power Solutions17.6.2026 14:00:00 CEST | Press release
Expansion of Colmar, France, manufacturing facility to more than double production capacity, enabling a structured industrial ramp-up Rehlko, a global energy resilience leader delivering innovative solutions across industrial energy systems, powertrain technologies, and home energy applications, joined Liebherr Group (“Liebherr”) on June 2 for the strategic capacity expansion ceremony at the Liebherr-Components facility in Colmar, France. This event marks a key milestone in the continued expansion of Rehlko’s strategic partnership with Liebherr and a significant step in scaling resilient power solutions for the next generation of digital infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617213506/en/ Liebherr and Rehlko celebrate the strategic capacity expansion of Liebherr-Components Colmar factory. From left to right: Brian Melka (President and CEO of Rehlko), Jan Liebherr (President of the Administrative B
FlexGen Launches International Operations, Delivering Software and Services to Meet Demand for Battery Storage in Europe17.6.2026 14:00:00 CEST | Press release
FlexGen expands market leadership by bringing its energy management system, including power plant controls, analytics, site-level SCADA, integration abilities, and lifecycle services, to Europe to reduce renewables curtailment and meet rising demand. FlexGen’s entry to the European market is improving operational performance, increasing availability, and unlocking greater returns for battery storage operators.FlexGen’s HybridOS® software can maximise site performance, reduce downtime, and extend the lifespan of energy storage assets by providing project owners real-time data and visibility into asset health and conditions. FlexGen Power Systems, LLC. ("FlexGen"), a leading battery energy storage solution and energy management software provider, announced today that it continues to grow its global business by building its presence in Europe to increase battery storage capacity on local grids, supporting energy reliability and affordability. FlexGen offers its energy management system, i
Moody’s Launches Decision-Grade AI Skills for Major AI Platforms17.6.2026 14:00:00 CEST | Press release
Launching today on Microsoft 365 Copilot Cowork, with availability expanding across compatible AI platforms Moody’s Corporation (NYSE: MCO) today announced the release of its first set of AI skills – purpose-built, platform-agnostic instruction kits that encode Moody’s analytical frameworks and connect AI agents to its decision-grade intelligence. Available across compatible AI platforms beginning with Microsoft 365 Copilot Cowork, Moody’s skills enable customers to execute complex analytical workflows through a single natural-language request, with outputs grounded in Moody’s proprietary ratings, research, and risk intelligence. “Moody’s is among the first financial data providers to deliver a full library of skills on an open standard, and today’s launch is just the beginning,” said Cristina Pieretti, Head of Digital Content and Innovation at Moody’s. “AI platforms are becoming the interface for financial decision-making, and the next phase of adoption will be defined by execution. S
Thredd and Sutton Bank Partner to Power U.S. Card Program Expansion for Global Brands17.6.2026 14:00:00 CEST | Press release
Partnership provides BIN Sponsorship and modern issuing processing, to launch and scale prepaid or debit card programs in the market Thredd, the AI-first issuer processing platform, today announced a strategic partnership with Sutton Bank, a leading sponsor bank and card issuer for fintechs and embedded finance use cases. Through the partnership, Sutton Bank will serve as a BIN sponsor for Thredd clients seeking to launch and scale prepaid and debit card programs in the United States. The partnership strengthens the U.S. market proposition for global fintechs and embedded finance providers by providing these organizations access to an established U.S. issuing bank partner with a long-standing track record supporting card programs across the fintech ecosystem. Sutton Bank has become widely recognized for its payments business, including its work with card networks, processors and program managers, as well as its role as a large BIN sponsor for the fintech community. Together, Thredd and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom